U.S. Markets closed

United Cannabis Granted Patent for Its Prana Bio Nutrient Line of Cannabinoid Based Products in the United States

DENVER, CO / ACCESSWIRE / August 15, 2017 / United Cannabis Corporation (CNAB) (the "Company" or "United Cannabis") today announced that the United States Patent and Trademark Office (USPTO) has issued US Patent #9730911 (the "Patent"), granting exclusive rights to its proprietary formulations based on compounds extracted from cannabis plant materials; more specifically, the composition of matter pertaining to the use of phytocannabinoids, cannabinoids, and specific terpene profiles in liquid form. This composition of matter patent provides protection for United Cannabis' proprietary formulations.

Earnest Blackmon, United Cannabis' Chief Executive Officer, commented on the approval, "This is a significant milestone for United Cannabis. Our primary objective has always been to develop unique and effective cannabinoid based products. This Patent is one the cornerstones of our business plan for obtaining FDA approval."

Tony Verzura, the Company's Chief Technology Officer, added, "I have spent the last 20 years working with cannabis as a patient, activist, caregiver, and innovator. Our patented innovations enabled our team to utilize chemical-free extractions and infusion methodologies for a wide range of accurately dosed products. These advances have helped us provide relief for thousands of patients suffering from a variety of ailments."

The patent protects the use of suspending both phytocannabinoids and cannabinoids with specific combinations of cannabis derived terpenes in liquid forms with an array of delivery methods including capsule, sublingual, topical, oral, suppository, and vaporization. Cannabinoids referenced in the application include ratios of tetrahydrocannabinolic acid (THCa), cannabidiolic acid (CBDa), tetrahydrocannabinol (THC), cannabinol (CBN), cannabidiol (CBD), cannabichromenic acid (CBCa), and cannabichromene (CBC).

About United Cannabis Corporation

United Cannabis Corporation is a biotechnology company dedicated to the development of phyto-therapeutic based products supported by patented technologies for the pharmaceutical, medical, and industrial markets. The Company has long advocated the application of cannabinoids for medical applications and is building a platform for designing targeted therapies to increase the quality of life for patients around the world. The Company's products are patent protected, first in class medicines with applications to a global market. United Cannabis trades on the OTCQB under the symbol CNAB.

For further information, please visit www.unitedcannabis.us.

Contact:

Staff@UnitedCannabis.us
Phone: 303-386-7321

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, and are subject to Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbors, created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

SOURCE: United Cannabis Corporation